On phase II , trial patients with p@-negative hypoxic tumours had worse loco-regional control with cisplatin and @FU compared with tirapazamine and cisplatin ( P < @ ) and worse failure-free survival ( hazard ratio = @ ; @ % confidence interval , @-@ @ ; P = @ ) .